Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
企業コードAGMB
会社名Agomab Therapeutics NV
上場日Feb 06, 2026
最高経営責任者「CEO」Knotnerus (Tim)
従業員数- -
証券種類Depository Receipt
決算期末Feb 06
本社所在地Posthoflei 1/6
都市
証券取引所NASDAQ OMX - NASDAQ BASIC
国Belgium
郵便番号2600
電話番号
ウェブサイトhttps://agomab.com/
企業コードAGMB
上場日Feb 06, 2026
最高経営責任者「CEO」Knotnerus (Tim)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし